Grant: Canada Postdoctoral Research Award (CPRA) program
Direct Payment
$140,000.00
Predicting tumor antigen specific TCR-pMHC binding using machine learning and thymic organoids
FY 2025-26
Summary
Our immune system relies on specialized cells called T cells to recognize and fight cancer cells. These T cells use unique receptors (T cell receptors) to identify, with very high specificity, markers (antigens) on cancer cells, similar to a lock recognizing its key. Despite recent advances in cancer targeting immunotherapy, predicting which T cells will effectively recognize cancer remains extremely challenging, limiting our ability to develop personalized cancer treatments.
We propose to create a new laboratory model that mimics how T cells develop in the human body, with a focus on generating T cells specifically designed to target cancer cells. By combining specialized supporting cells (thymic epithelial cells) with developing immune cells in a dish, we can generate T cells that recognize a diverse set of antigens. Using this approach, we will then systematically test these T cells against a comprehensive library of cancer-specific antigens to identify which T cell receptors bind which antigen. We can then train machine learning algorithms with this dataset to predict the ability of patient-specific T cell receptors to recognize clinically relevant cancer antigens.
This research will advance our ability to design novel T cell receptor-based immunotherapies. Our computational tools will improve prediction of which T cells work best for individual cancer patients, enabling more personalized treatments. Additionally, our work will create a valuable resource for other scientists studying cancer immunotherapies.
Beyond cancer treatment, this research will help decode the fundamental "rules" governing the language of our adaptive immune system. Our findings may provide insights into how the immune system recognizes other threats, potentially benefiting research into autoimmune and infectious diseases.
Department
Program
Canada Postdoctoral Research Award (CPRA) program
Recipient
Location
United Kingdom
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
537860
Name
Atif Jawairia
Country
United Kingdom
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Canada Postdoctoral Research Award - A
Projecttitle
Predicting tumor antigen specific TCR-pMHC binding using machine learning and thymic organoids
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Canada Postdoctoral Research Award (CPRA) program
Keyworddelim
Antigen Recognition; Induced Pluripotent Stem Cells; Large Language Modelling; T Cell Receptor; Thymic Epithelial Cells; Thymus; Tumor Antigens
Abstract
Our immune system relies on specialized cells called T cells to recognize and fight cancer cells. These T cells use unique receptors (T cell receptors) to identify, with very high specificity, markers (antigens) on cancer cells, similar to a lock recognizing its key. Despite recent advances in cancer targeting immunotherapy, predicting which T cells will effectively recognize cancer remains extremely challenging, limiting our ability to develop personalized cancer treatments.
We propose to create a new laboratory model that mimics how T cells develop in the human body, with a focus on generating T cells specifically designed to target cancer cells. By combining specialized supporting cells (thymic epithelial cells) with developing immune cells in a dish, we can generate T cells that recognize a diverse set of antigens. Using this approach, we will then systematically test these T cells against a comprehensive library of cancer-specific antigens to identify which T cell receptors bind which antigen. We can then train machine learning algorithms with this dataset to predict the ability of patient-specific T cell receptors to recognize clinically relevant cancer antigens.
This research will advance our ability to design novel T cell receptor-based immunotherapies. Our computational tools will improve prediction of which T cells work best for individual cancer patients, enabling more personalized treatments. Additionally, our work will create a valuable resource for other scientists studying cancer immunotherapies.
Beyond cancer treatment, this research will help decode the fundamental "rules" governing the language of our adaptive immune system. Our findings may provide insights into how the immune system recognizes other threats, potentially benefiting research into autoimmune and infectious diseases.
Competitiondate
202509
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Atif, Jawairia
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~